Daxor (NASDAQ:DXR) versus LifeStance Health Group (NASDAQ:LFST) Critical Contrast

Daxor (NASDAQ:DXR) and LifeStance Health Group (NASDAQ:LFST) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Daxor and LifeStance Health Group, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	1	1	0	2.50
LifeStance Health Group	2	0	5	1	2.63

Daxor presently has a consensus price target of $25.00, indicating a potential upside of 79.86%. LifeStance Health Group has a consensus price target of $8.50, indicating a potential upside of 54.26%. Given Daxor’s higher probable upside, analysts plainly believe Daxor is more favorable than LifeStance Health Group.

Insider & Institutional Ownership

1.3% of Daxor shares are owned by institutional investors. Comparatively, 85.5% of LifeStance Health Group shares are owned by institutional investors. 59.5% of Daxor shares are owned by insiders. Comparatively, 3.2% of LifeStance Health Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Daxor and LifeStance Health Group’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
LifeStance Health Group	-1.23%	-1.11%	-0.76%

Risk & Volatility

Daxor has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, LifeStance Health Group has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.

Valuation and Earnings

This table compares Daxor and LifeStance Health Group”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
LifeStance Health Group	$1.25 billion	1.71	-$57.44 million	($0.05)	-110.20

Daxor has higher earnings, but lower revenue than LifeStance Health Group.

Summary

LifeStance Health Group beats Daxor on 6 of the 11 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About LifeStance Health Group

LifeStance Health Group, Inc., through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy. It treats a range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. In addition, the company operates an outpatient mental health platform, as well as offers patient care virtually through its online delivery platform or in-person at its centers. LifeStance Health Group, Inc. was founded in 2017 and is headquartered in Scottsdale, Arizona.